OBJECTIVE: The aim of this study was to examine associations of smoking at the time of diagnosis with the risk of prostate cancer death in a population-based cohort of men with prostate cancer. METHODS: Data were from 752 prostate cancer patients aged 40-64 years, who were enrolled in a case-control study and under long-term follow-up for mortality. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for associations between smoking and prostate cancer-specific and other cause mortality. RESULTS: Compared to never smoking, smoking at the time of diagnosis was associated with a significant increase in risk of prostate cancer-specific mortality. After controlling for demographic characteristics, Gleason grade, stage at diagnosis, and primary treatment, the HR was 2.66 (95% CI: 1.10-6.43). CONCLUSIONS: Smoking at the time of diagnosis, independent of key clinical prognostic factors, is associated with an increased risk of prostate cancer death.
OBJECTIVE: The aim of this study was to examine associations of smoking at the time of diagnosis with the risk of prostate cancer death in a population-based cohort of men with prostate cancer. METHODS: Data were from 752 prostate cancerpatients aged 40-64 years, who were enrolled in a case-control study and under long-term follow-up for mortality. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for associations between smoking and prostate cancer-specific and other cause mortality. RESULTS: Compared to never smoking, smoking at the time of diagnosis was associated with a significant increase in risk of prostate cancer-specific mortality. After controlling for demographic characteristics, Gleason grade, stage at diagnosis, and primary treatment, the HR was 2.66 (95% CI: 1.10-6.43). CONCLUSIONS: Smoking at the time of diagnosis, independent of key clinical prognostic factors, is associated with an increased risk of prostate cancer death.
Authors: Corinne E Joshu; Alison M Mondul; Cari L Meinhold; Elizabeth B Humphreys; Misop Han; Patrick C Walsh; Elizabeth A Platz Journal: J Natl Cancer Inst Date: 2011-04-15 Impact factor: 13.506
Authors: Daniel M Moreira; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Matthew R Cooperberg; Paolo Boffetta; Stephen J Freedland Journal: Cancer Date: 2013-10-11 Impact factor: 6.860
Authors: Daniel M Moreira; Jodi A Antonelli; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland Journal: Urology Date: 2010-04-09 Impact factor: 2.649
Authors: Taro Iguchi; Ching Y Wang; Nicolas B Delongchamps; Robert Sunheimer; Tatsuya Nakatani; Gustavo de la Roza; Gabriel P Haas Journal: Anticancer Res Date: 2008 Sep-Oct Impact factor: 2.480